Title: 4-week GLP immunotoxicity assessment of lactoferrin alpha produced by Komagataella phaffii in Sprague Dawley rats

Ross Peterson, Robert B Crawford, Lance K Blevins, Norbert E Kaminski, Anthony J Clark, Carrie-Anne Malinczak
{"title":"Title: 4-week GLP immunotoxicity assessment of lactoferrin alpha produced by Komagataella phaffii in Sprague Dawley rats","authors":"Ross Peterson, Robert B Crawford, Lance K Blevins, Norbert E Kaminski, Anthony J Clark, Carrie-Anne Malinczak","doi":"10.1101/2024.08.16.608335","DOIUrl":null,"url":null,"abstract":"Oral toxicity and toxicokinetic properties of human lactoferrin (LF) alpha produced in Komagataella Phaffii (effera™) were investigated in adult Sprague-Dawley rats over a 28-day period under good laboratory practice conditions. Main study dosing used groups of 10 rats/sex/dose, and a secondary study evaluating toxicokinetic parameters used 6 rats/sex/dose. The vehicle control group received sodium citrate buffer, test groups received daily doses of 200, 600, and 2000 mg of effera™ per kg body weight, and the comparative control group received 2000 mg bovine LF (bLF)/kg body weight per day. T-cell dependent antibody response against keyhole limpet hemocyanin and immunophenotyping of the spleen were performed as measures of immunotoxicity. Clinical observations, body weight, hematology, coagulation, clinical chemistry, urinalysis, immunotoxicity, gross necropsy, and histopathology were assessed. Toxicokinetic parameters were analyzed as an indication of LF bioavailability, and anti-LF antibody assays were conducted to detect antibodies produced against LF to measure immunogenicity. No treatment related toxicologically significant changes were observed. Based on the absence of toxicologically relevant changes, effera™ is well tolerated in rats at doses up to 2000 mg rhLF/kg/day, an amount ~400 times that of the estimated daily intake at the 90th percentile proposed for human adult use.","PeriodicalId":501518,"journal":{"name":"bioRxiv - Pharmacology and Toxicology","volume":"25 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"bioRxiv - Pharmacology and Toxicology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.08.16.608335","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Oral toxicity and toxicokinetic properties of human lactoferrin (LF) alpha produced in Komagataella Phaffii (effera™) were investigated in adult Sprague-Dawley rats over a 28-day period under good laboratory practice conditions. Main study dosing used groups of 10 rats/sex/dose, and a secondary study evaluating toxicokinetic parameters used 6 rats/sex/dose. The vehicle control group received sodium citrate buffer, test groups received daily doses of 200, 600, and 2000 mg of effera™ per kg body weight, and the comparative control group received 2000 mg bovine LF (bLF)/kg body weight per day. T-cell dependent antibody response against keyhole limpet hemocyanin and immunophenotyping of the spleen were performed as measures of immunotoxicity. Clinical observations, body weight, hematology, coagulation, clinical chemistry, urinalysis, immunotoxicity, gross necropsy, and histopathology were assessed. Toxicokinetic parameters were analyzed as an indication of LF bioavailability, and anti-LF antibody assays were conducted to detect antibodies produced against LF to measure immunogenicity. No treatment related toxicologically significant changes were observed. Based on the absence of toxicologically relevant changes, effera™ is well tolerated in rats at doses up to 2000 mg rhLF/kg/day, an amount ~400 times that of the estimated daily intake at the 90th percentile proposed for human adult use.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
标题: 在 Sprague Dawley 大鼠体内对 Komagataella phaffii 产生的乳铁蛋白 alpha 进行为期 4 周的 GLP 免疫毒性评估
在良好实验室规范条件下,对 Komagataella Phaffii(effera™)生产的人乳铁蛋白(LF)α的口服毒性和毒代动力学特性进行了为期 28 天的研究。主要研究剂量为每组 10 只大鼠/性别/剂量,评估毒物动力学参数的辅助研究剂量为每组 6 只大鼠/性别/剂量。载体对照组使用柠檬酸钠缓冲液,试验组每天每公斤体重使用 200、600 和 2000 毫克 effera™,对比对照组每天每公斤体重使用 2000 毫克牛 LF (bLF)。作为免疫毒性的测量指标,进行了针对匙孔帽贝血蓝蛋白的 T 细胞依赖性抗体反应和脾脏免疫分型。对临床观察、体重、血液学、凝血、临床化学、尿液分析、免疫毒性、大体尸检和组织病理学进行了评估。对毒物动力学参数进行了分析,以显示 LF 的生物利用度,并进行了抗 LF 抗体检测,以检测针对 LF 产生的抗体,从而衡量免疫原性。没有观察到与治疗有关的毒理学上的重大变化。根据未发现的毒理学相关变化,effera™在大鼠体内的耐受性良好,剂量最高可达2000毫克rhLF/公斤/天,约为建议人类成人使用的第90百分位数估计日摄入量的400倍。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Quinoline synergy and reduced use: a study of pharmacodynamic interactions In vitro and in vivo evaluation of Ulva lactuca for wound healing In Vitro Evaluation of Anti-Inflammatory, Anti-Plaque Efficacy, and Biocompatibility of Norway Spruce (Picea abies) Resin Extract for Oral Care Applications Daphnids Can Safeguard the Use of Alternative Bioassays to the Acute Fish Toxicity Test: A Focus on Neurotoxicity Qing-Luo-Yin-induced SIRT1 inhibition contributes to the immune improvement of adjuvant-induced arthritis rats
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1